KR101466633B1 - Preparation method for ultra-high pressure extract of onion having reducing activity of serum cholesterol and pharmaceutical or neutraceutical composition comprising the extract of onion as an effective ingredient - Google Patents
Preparation method for ultra-high pressure extract of onion having reducing activity of serum cholesterol and pharmaceutical or neutraceutical composition comprising the extract of onion as an effective ingredient Download PDFInfo
- Publication number
- KR101466633B1 KR101466633B1 KR1020130048451A KR20130048451A KR101466633B1 KR 101466633 B1 KR101466633 B1 KR 101466633B1 KR 1020130048451 A KR1020130048451 A KR 1020130048451A KR 20130048451 A KR20130048451 A KR 20130048451A KR 101466633 B1 KR101466633 B1 KR 101466633B1
- Authority
- KR
- South Korea
- Prior art keywords
- onion
- high pressure
- ultra
- extract
- quercetin
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 64
- 241000234282 Allium Species 0.000 title claims abstract description 55
- 235000002732 Allium cepa var. cepa Nutrition 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 title description 19
- 239000004615 ingredient Substances 0.000 title description 2
- 230000001603 reducing effect Effects 0.000 title 1
- 229940072113 onion extract Drugs 0.000 claims abstract description 59
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 8
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 7
- 208000008589 Obesity Diseases 0.000 claims abstract description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 7
- 235000020824 obesity Nutrition 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 87
- 230000002401 inhibitory effect Effects 0.000 abstract description 36
- 150000003464 sulfur compounds Chemical class 0.000 abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 238000007796 conventional method Methods 0.000 abstract description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 38
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 38
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 38
- 229960001285 quercetin Drugs 0.000 description 38
- 235000005875 quercetin Nutrition 0.000 description 38
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 30
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 30
- 239000000843 powder Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YWHLKYXPLRWGSE-UHFFFAOYSA-N Dimethyl trisulfide Chemical compound CSSSC YWHLKYXPLRWGSE-UHFFFAOYSA-N 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- OIUBYZLTFSLSBY-HMGRVEAOSA-N quercetin 4'-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)C=C1O OIUBYZLTFSLSBY-HMGRVEAOSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- -1 3-hydroxy-3-methylglutaryl Chemical group 0.000 description 4
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 4
- 229940008075 allyl sulfide Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 description 4
- UBAXRAHSPKWNCX-UHFFFAOYSA-N diallyl trisulfide Chemical compound C=CCSSSCC=C UBAXRAHSPKWNCX-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- RPVIQWDFJPYNJM-UHFFFAOYSA-N Ganodermic acid Ja Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(O)C(O)C(CO)O2)O)C=C1O RPVIQWDFJPYNJM-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QJTYCCFDQWFJHU-UHFFFAOYSA-N Quercetin-5-O-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C(O)=C(C=1C=C(O)C(O)=CC=1)O2 QJTYCCFDQWFJHU-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- VLXBWPOEOIIREY-UHFFFAOYSA-N dimethyl diselenide Natural products C[Se][Se]C VLXBWPOEOIIREY-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 3
- RPVIQWDFJPYNJM-DEFKTLOSSA-N quercetin 3,4'-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1O RPVIQWDFJPYNJM-DEFKTLOSSA-N 0.000 description 3
- OPJZLUXFQFQYAI-GNPVFZCLSA-N quercetin 3-O-beta-D-glucofuranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OPJZLUXFQFQYAI-GNPVFZCLSA-N 0.000 description 3
- SZDMSNWMQAMVTJ-UHFFFAOYSA-N quercetin-3-O-glucoside Natural products OC1OC(COC2=C(C(=O)c3cc(O)cc(O)c3O2)c4ccc(O)c(O)c4)C(O)C(O)C1O SZDMSNWMQAMVTJ-UHFFFAOYSA-N 0.000 description 3
- FZKBNCDAGYDHTP-UHFFFAOYSA-N quercetin-3-O-glycoside Natural products OC1C(O)C(O)C(O)OC1COC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O FZKBNCDAGYDHTP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FCSSPCOFDUKHPV-UHFFFAOYSA-N 2-Propenyl propyl disulfide Chemical compound CCCSSCC=C FCSSPCOFDUKHPV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- RPVIQWDFJPYNJM-MPPJEPTCSA-N Quercetin 3,4'-di-O-beta-D-glucopyranoside Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(C2=C(O[C@H]3[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)C(=O)c3c(O)cc(O)cc3O2)cc1 RPVIQWDFJPYNJM-MPPJEPTCSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003243 quercetin Chemical class 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/46—Ultra high pressure
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 400 내지 800 MPa로 초고압에서도 매우 높은 압력으로 처리한 초고압 양파 추출물은 종래 통상의 방법으로 제조한 양파 추출물과 퀘르세틴 함량은 유사하거나 오히려 상대적으로 낮음에도 불구하고, 혈중 콜레스테롤 농도를 저하시키는 HMG-CoA 환원효소 억제 활성이 현저히 증대되고, 양파 특유의 불쾌취를 부여하는 황 화합물의 함량이 낮아지므로, 양파 냄새로 인한 거부감 없이 혈중 콜레스테롤 고함량에 의해 유발되는 비만, 고지혈증, 혈전증, 동맥경화, 뇌졸증 또는 심근경색의 치료 및 예방용 약학 조성물이나 혈중 콜레스테롤 강하용 건강기능식품 조성물의 유효성분으로 활용될 수 있다.In the present invention, the ultra high pressure onion extract treated with a very high pressure even at an ultra-high pressure of 400 to 800 MPa has a similar or even relatively low quercetin content to the onion extract prepared by conventional methods, -COA < / RTI > reductase inhibitory activity is remarkably increased and the content of sulfur compound giving unpleasant odor unique to onion is lowered. Therefore, it is possible to prevent obesity, hyperlipemia, thrombosis, arteriosclerosis, A pharmaceutical composition for the treatment and prevention of stroke or myocardial infarction, and a health functional food composition for lowering blood cholesterol.
Description
본 발명은 초고압을 이용하여 천연 식물로부터 유효성분을 추출하는 방법에 관한 것이고, 또한 그 추출물을 유효성분으로 하는 혈중 콜레스테롤 강하용 건강기능식품 조성물, 또는 혈중 콜레스테롤 고함량에 의해 유발되는 비만, 고지혈증, 혈전증, 동맥경화, 뇌졸증 또는 심근경색의 치료 및 예방용 약학 조성물에 관한 것이다.
The present invention relates to a method for extracting an active ingredient from a natural plant by using ultrahigh pressure, and also relates to a composition for extracting a health functional food for lowering cholesterol comprising the extract as an active ingredient, or a composition for preventing obesity, hyperlipidemia, Thrombosis, arteriosclerosis, stroke, or myocardial infarction.
혈중 콜레스테롤은 비만, 고지혈증, 혈전증, 동맥경화, 뇌졸증 또는 심근경색 발생의 주요 위험인자로서, 체내에서 적절하게 콜레스테롤의 조절이 일어나면 혈장과 조직의 경우, 콜레스테롤 축적이 일어나지 않으나 체내 콜레스테롤의 수치가 높아지게 되면 고콜레스테롤 혈증이 나타나게 되며, 콜레스테롤 대사조절에 이상이 발생하여 LDL, HDL 콜레스테롤 등 지단백 성분이 양적으로 변화하게 된다.Blood cholesterol is a major risk factor for obesity, hyperlipidemia, thrombosis, arteriosclerosis, stroke or myocardial infarction. When cholesterol is properly controlled in the body, cholesterol accumulation does not occur in plasma and tissues, but when the level of cholesterol in the body becomes high Hypercholesterolemia, and cholesterol metabolism control abnormalities, such as LDL, HDL cholesterol and other components of the lipoproteins will change quantitatively.
이러한 혈중 콜레스테롤의 축적으로 인해 발생되는 질환을 치료하거나 예방하기 위해서, 약물요법이 사용되고 있는데, 대표적인 것으로는 콜레스테롤 합성 경로에 의한 3-히드록시-3-메틸글루타릴 보조인자 A(HMG-CoA)로부터 발론산(valonic acid)의 합성을 억제하는 것에 의해 콜레스테롤 생합성을 억제하는, HMG-CoA 환원효소 억제제(예를 들면, 메바스타틴) 및 담즙산 흡착제(bile acid adsorber)(음이온 교환 수지)와 같은 약물이 있으며, 콜레스테롤 강하제로서 니코틴산, 콜레스티라민, 클로피브레이트(clofibrate), 네오마이신(neomycin), 식물 스테롤(plant sterols), 트리파라놀, D-티로신 및 에스트로겐호르몬 등이 사용되고 있다.In order to treat or prevent diseases caused by the accumulation of blood cholesterol, pharmacotherapy has been used. Typical examples include 3-hydroxy-3-methylglutaryl cofactor A (HMG-CoA) Such as HMG-CoA reductase inhibitors (e.g., mevastatin) and bile acid adsorbers (anion exchange resins), which inhibit cholesterol biosynthesis by inhibiting the synthesis of valonic acid from the body And cholesterol lowering agents such as nicotinic acid, cholestyramine, clofibrate, neomycin, plant sterols, tripolanol, D-tyrosine and estrogen hormone are used.
한편 양파는 백합 과에 속하는 다년생식물로 인경은 직경이 10cm에 달하며 편구형, 또는 구형이다. 9월에 화경 끝에서 큰 화서가 자라고 자루가 있는 많은 꽃이 산형으로 달리며 인경은 식용으로 사용한다. 양파의 성분으로는 주로 퀘르세틴(quercetin) 배당체인 quercetin 3-O-glucoside, quercetin 3,4'-diglucoside, quercetin 4'-glucoside 등이 알려져 있으며, 매운 맛을 내는 프로필 아릴디설파이드(propyl allyldisulfide) 등 황화 아릴 계통의 화합물이 다수 함유되어 있는 것으로 나타났다. 퀘르세틴(quercetin)은 식용 부위에는 거의 함유되어 있지 않으나, 갈색의 겉껍질에 다량 함유되어 있어(건조 g당 약 8.3 mg) 그 함량은 식용부위의 수십~수백 배에 달하는 것으로 알려져 있으며, 상기 퀘르세틴(quercetin)은 항염증작용, 뇌세포 보호활성, 항암작용, 항당뇨, 항비만, 항고혈압 등 각종 생리활성을 나타내는 것으로 보고되어 있는 화합물이다.Meanwhile, onion is a perennial plant belonging to the lily family, and its diameter is 10cm in diameter and is spherical or spherical. In September, a large flower grows from the tip of the flower, and many flowers with a sack run in a mountain shape. Quercetin 3-O-glucoside, quercetin 3,4'-diglucoside, quercetin 4'-glucoside and the like are known as the quercetin glycosides, and propyl allyldisulfide, It was found that a large number of aryl-based compounds were contained. Although quercetin is hardly contained in the edible part, it is contained in a large amount in the brown shell (about 8.3 mg per dry g), and its content is known to be several tens to several hundred times as large as that of the edible part, and quercetin quercetin) has been reported to exhibit various physiological activities such as anti-inflammatory action, brain cell protective activity, anti-cancer activity, anti-diabetic, anti-obesity, and anti-hypertensive.
한국공개특허 제10-2011-0121239호 및 제10-2011-0100882호에서는 양파껍질 추출물 또는 이로부터 분리한 퀘르세틴 화합물이 혈장 내 중성지방 및 총 코레스테롤 함량을 감소시켜 지질대사 질환의 예방 및 치료에 사용될 수 있음을 개시하고 있고, 한국공개특허 제10-2012-0127933호는 양파껍질을 주정으로 추출한 후 다시 초산에틸로 추출하는 퀘르세틴 함량이 높은 양파 추출물의 제조방법을 개시하고 있으며, 한국공개특허 제10-2012-0085585호에서도 양파껍질에서 퀘르세틴을 높은 함량으로 추출하기 위하여 주정으로 추출한 후, 재차 주정을 투입하여 반복 추출하는 방법을 개시하고 있고, 한국공개특허 제10-2011-0029893호에서는 양파로부터 퀘르세틴을 고함량으로 추출하기 위해 아임계 추출을 이용하는 방법을 개시하고 있으며, 한국등록특허 제10-1017594호는 퀘르세틴 함량이 증가된 양파 추출물을 얻기 위하여 양파의 에탄올 추출물을 메주균 액을 접종하여 발효시키는 방법을 개시하고 있다.Korean Patent Laid-open Nos. 10-2011-0121239 and 10-2011-0100882 disclose that onion skin extract or quercetin compounds isolated therefrom reduce the triglyceride and total cholesterol contents in plasma and are used for prevention and treatment of lipid metabolic diseases Korean Patent Laid-Open Publication No. 10-2012-0127933 discloses a method for producing an onion extract having a high quercetin content, which extracts an onion skin with alcohol and then extracts it with ethyl acetate. Korean Patent Laid- -2012-0085585 discloses a method for extracting quercetin in a high content from an onion skin and then extracting it repeatedly by injecting the same again. In Korean Patent Publication No. 10-2011-0029893, quercetin , And Korean Patent No. 10-1017594 discloses a method of using subcritical extraction to extract a high content of quercetin It discloses a method for fermenting ethanol extract of onion was inoculated a bacterium Meju solution to obtain the onion extract the content is increased.
또한 양파 추출물의 자극적인 맛과 특유의 냄새 제거를 위해서 한국공개특허 제10-2004-0080505호는 양파의 껍질을 벗기지 않고 동결한 후, 껍질을 제거하고 고압솥에서 가열한 후 압착, 여과하는 양파 추출물의 제조방법을 개시하고 있고, 한국등록특허 제10-0895969호에는 양파 고유의 불쾌취를 제거하기 위하여 감초, 당귀, 갈근, 천궁, 소엽 및 다시마가 조합된 천연 조향제를 함께 함유시킨 양파 추출물에 대해 개시하고 있다.Korean Patent Laid-Open Publication No. 10-2004-0080505 discloses a method for removing irritating taste and specific odor of onion extract by freezing the onion's skin without removing the skin, removing the skin, heating it in a high pressure cooker, Korean Patent No. 10-0895969 discloses a method for producing an extract of onion which contains a natural mannitol combined with licorice, Angelica gigas, Puerariae radix, .
그러나 양파를 400 내지 800 MPa로 초고압에서도 매우 높은 압력으로 처리한 후 추출할 경우, 종래 통상의 방법으로 제조한 양파 추출물과 퀘르세틴 함량은 유사하거나 오히려 상대적으로 낮음에도 불구하고, 혈중 콜레스테롤 농도를 저하시키는 HMG-CoA 환원효소 억제 활성이 현저히 증대되고, 이때 양파 특유의 불쾌취를 부여하는 황 화합물의 함량이 낮아진다는 것을 확인하게 되어 본 발명을 완성하였다.
However, when the onion is extracted at 400 to 800 MPa at a very high pressure even at a very high pressure, the extract of quercetin and the onion extract prepared by conventional methods have a similar or rather low level of serum cholesterol It was confirmed that the HMG-CoA reductase inhibitory activity was remarkably increased, and at this time, the content of the sulfur compound giving unpleasant odor peculiar to the onion was lowered, thus completing the present invention.
본 발명은 혈중 콜레스테롤 농도를 저하시키는 HMG-CoA 환원효소 억제 활성이 현저히 증대되며, 양파 특유의 불쾌취를 부여하는 황 화합물의 함량이 낮은 초고압 양파 추출물의 제조방법을 제공하기 위한 것이다.The present invention provides a method for producing an ultra high-pressure onion extract having a low content of sulfur compounds that significantly increases the inhibitory activity of HMG-CoA reductase which lowers blood cholesterol concentration and gives unpleasant odors specific to onions.
또한 본 발명은 초고압 양파 추출물을 유효성분으로 포함하는 혈중 콜레스테롤 강하용 건강기능식품 조성물을 제공하기 위한 것이다.The present invention also provides a health functional food composition for lowering blood cholesterol comprising an ultra high pressure onion extract as an active ingredient.
또한 본 발명은 초고압 양파 추출물을 유효성분으로 포함하는 혈중 콜레스테롤 고함량에 의해 유발되는 비만, 고지혈증, 혈전증, 동맥경화, 뇌졸증 또는 심근경색의 치료 및 예방용 약학 조성물을 제공하기 위한 것이다.
The present invention also provides a pharmaceutical composition for the treatment and prevention of obesity, hyperlipidemia, thrombosis, arteriosclerosis, stroke or myocardial infarction induced by a high cholesterol content in blood containing an ultra high pressure onion extract as an active ingredient.
본 발명은 양파를 400 내지 800 MPa에서 0.5 분 내지 5 시간 초고압 처리하는 단계; 및 상기 초고압 처리된 양파를 착즙하거나 또는 추출하는 단계;를 포함하는 혈중 콜레스테롤 농도 저하 활성을 갖는 초고압 양파 추출물의 제조방법을 제공한다.The present invention relates to a process for producing an onion by treating an onion at 400 to 800 MPa at an ultra-high pressure for 0.5 to 5 hours; And extracting or extracting the ultra-high pressure treated onion. The present invention also provides a method for producing an ultra-high pressure onion extract having a blood cholesterol concentration lowering activity.
상기 초고압 처리는 압력은 400 내지 800 MPa, 바람직하게는 450 내지 700 MPa, 더욱 바람직하게는 500 내지 600 MPa로 처리하고, 초고압 처리 시간은 0.5 분 내지 5 시간, 바람직하게는 1 분 내지 1 시간, 더욱 바람직하게는 2 분 내지 20 분 처리한다. 상기 초고압 처리 온도는 특별히 한정할 필요는 없지만 별도의 가열 또는 냉각 없이 실온에서 처리할 수 있고, 바람직하게는 0 내지 50 ℃, 더욱 바람직하게는 5 내지 40 ℃, 가장 바람직하게는 10 내지 35 ℃에서 처리한다.The ultrahigh pressure treatment is performed at a pressure of 400 to 800 MPa, preferably 450 to 700 MPa, more preferably 500 to 600 MPa, and the ultrahigh pressure treatment time is 0.5 to 5 hours, preferably 1 to 1 hour, More preferably 2 to 20 minutes. The ultrahigh-pressure treatment temperature is not particularly limited, but it can be treated at room temperature without any additional heating or cooling, preferably at 0 to 50 캜, more preferably at 5 to 40 캜, most preferably at 10 to 35 캜 .
상기 초고압 처리 압력이 상기 하한치 미만인 경우에는 HMG-CoA 환원효소 억제 활성이 낮아 혈중 콜레스테롤 강하 효과가 낮고 동시에 황 화합물의 함량을 낮출 수 없다. 또한 상기 초고압 처리 압력이 상기 하한치 미만인 경우에는 지표성분으로 퀘르세틴 4'-글리코시드와 퀘르세틴 3,4'-글리코시드의 중량비가 1 : 8 미만이 된다. 또한 상기 초고압 처리 압력이 상기 상한치를 초과하는 경우는, 초고압 처리를 위한 장치 및 처리 비용은 상승함에도 HMG-CoA 환원효소 억제 활성의 변화는 거의 없다.When the ultrahigh pressure treatment pressure is lower than the lower limit value, the HMG-CoA reductase inhibitory activity is low and the blood cholesterol lowering effect is low and the sulfur compound content can not be lowered at the same time. When the ultrahigh pressure treatment pressure is lower than the lower limit, the weight ratio of quercetin 4'-glycoside to quercetin 3,4'-glycoside as the indicator component is less than 1: 8. When the ultrahigh pressure treatment pressure exceeds the upper limit value, the HMG-CoA reductase inhibitory activity hardly changes even though the apparatus and treatment cost for the ultrahigh pressure treatment are increased.
상기 초고압 처리 시간은 초고압 처리를 통해 양파의 세포벽 조직이 파괴될 수 있는 매우 짧은 시간이면 충분하고, 초고압 처리 시간이 상기 상한치를 초과하더라도 초고압 처리를 위한 장치 및 처리 비용은 상승함에도 HMG-CoA 환원효소 억제 활성의 변화는 거의 없다.The ultra-high pressure treatment time is sufficient for a very short time in which the cell wall tissue of the onion can be destroyed by the ultra high pressure treatment. Even if the ultra high pressure treatment time exceeds the upper limit value, the apparatus and treatment cost for the ultra high pressure treatment are increased, but the HMG- There is little change in inhibitory activity.
종래 기술들에서 혈중 콜레스테롤 농도를 저하시키는 활성을 갖는 양파의 유효성분으로 알려진 퀘르세틴 함량은 본 발명에서 초고압 처리 압력을 높일수록 오히려 낮아지는 경향을 나타내었고, 퀘르세틴 함량과 HMG-CoA 환원효소 억제 활성은 비례하지 않는 것을 확인할 수 있었다. 또한 종래의 양파 열수 추출물이나 100 MPa로 처리한 초고압 처리 양파 추출물에서는 퀘르세틴 4'-글리코시드와 퀘르세틴 3,4'-글리코시드의 중량비가 1 : 4 정도 였으나, 초고압 처리 압력을 높일수록 퀘르세틴 3,4'-글리코시드의 비율이 높아지고, 본 발명에서와 같이 400 MPa 이상에서는 퀘르세틴 4'-글리코시드와 퀘르세틴 3,4'-글리코시드의 중량비가 1 : 8 내지 1 : 10 이 됨을 확인할 수 있었다. 이를 통하여 본 발명의 초고압 양파 추출물은 400 MPa 이상의 초고압 처리를 통해 양파에서 퀘르세틴과 함께 HMG-CoA 환원효소 억제 활성을 가지는 별도의 활성 성분이 추가로 추출되기 용이하게 되었음을 추정할 수 있었다.The quercetin content, which is known as an active ingredient of onion having an activity to lower blood cholesterol concentration in the prior art, tended to be lowered as the ultrahigh pressure treatment pressure was increased in the present invention. Quercetin content and HMG-CoA reductase inhibitory activity I can confirm that it is not proportional. In addition, the weight ratio of quercetin 4'-glycoside to quercetin 3,4'-glycoside was about 1: 4 in conventional onion hot-water extract or ultra-high-pressure onion extract treated with 100 MPa. However, quercetin 3, 4'-glycoside, and the weight ratio of quercetin 4'-glycoside to quercetin 3,4'-glycoside is 1: 8 to 1:10 at 400 MPa or more as in the present invention. Thus, it can be estimated that the ultra high-pressure onion extract of the present invention can be further extracted with quercetin and an additional active ingredient having HMG-CoA reductase inhibitory activity in an onion at an ultrahigh pressure of 400 MPa or more.
본 발명의 초고압 양파 추출물의 제조방법에서, 상기 초고압 처리된 양파를 착즙하거나 또는 추출하는 단계에서 착즙하거나 또는 추출하기 전에, 상기 초고압 처리된 양파에 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합용매를 혼합하는 것이 바람직하다.In the method for producing an ultra high pressure onion extract of the present invention, it is preferable to add water, a lower alcohol having 1 to 4 carbon atoms, or a mixture thereof to the ultra high pressure treated onion before juicing or extracting the ultra high pressure treated onion, It is preferable to mix the solvent.
본 발명의 초고압 양파 추출물의 제조방법에서, 상기 초고압 처리된 양파에 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합용매를 혼합하기 전에, 상기 초고압 처리된 양파를 분쇄 또는 절단하는 것이 바람직하다.In the method for producing an ultra high pressure onion extract of the present invention, it is preferable to crush or cut the ultra high pressure treated onion before mixing the water, the lower alcohol having 1 to 4 carbon atoms, or the mixed solvent thereof with the ultra high pressure treated onion.
본 발명의 초고압 양파 추출물의 제조방법에서, 상기 초고압 처리된 양파를 착즙하거나 또는 추출하는 단계에서, 착즙하거나 또는 추출한 후에, 착즙액 또는 추출액을 여과하는 것이 바람직하다.In the method for producing an ultra high-pressure onion extract of the present invention, it is preferable to filter the juice or extract after juicing or extraction in the step of juicing or extracting the hyper-pressure-treated onion.
본 발명의 초고압 양파 추출물의 제조방법에서, 상기 초고압 처리된 양파를 추출하는 단계의 추출시간은 1 분 내지 2 시간인 것이 바람직하고, 추출시간의 상한치를 초과할 경우 오히려 HMG-CoA 환원효소 억제 활성이 감소한다.In the method for producing an ultra high-pressure onion extract according to the present invention, the extraction time of the step of extracting the ultra-high-pressure onion is preferably 1 minute to 2 hours, and when the upper limit of the extraction time is exceeded, the HMG-CoA reductase inhibitory activity .
본 발명의 초고압 양파 추출물의 제조방법에서, 상기 초고압 양파 추출물은 지표성분으로 퀘르세틴 4'-글리코시드와 퀘르세틴 3,4'-글리코시드의 중량비가 1:8 내지 1:10 인 것이 바람직하다.
In the method for producing an ultra high-pressure onion extract of the present invention, it is preferable that the weight ratio of quercetin-4'-glycoside to quercetin-3,4'-glycoside as an indicator component is 1: 8 to 1:10.
본 발명은 상기 제조방법으로 제조된 혈중 콜레스테롤 농도 저하 활성을 갖는 초고압 양파 추출물을 유효성분으로 하는 혈중 콜레스테롤 강하용 건강기능식품 조성물을 제공한다.The present invention provides a health functional food composition for lowering blood cholesterol comprising an ultra-high pressure onion extract having blood cholesterol concentration lowering activity produced by the above-described method as an active ingredient.
본 발명은 400 내지 800 MPa에서 0.5 분 내지 5 시간 초고압 처리되고, 지표성분으로 퀘르세틴 4'-글리코시드와 퀘르세틴 3,4'-글리코시드를 1:8 내지 1:10로 포함하는, 초고압 양파 추출물을 유효성분으로 하는 혈중 콜레스테롤 강하용 건강기능식품 조성물을 제공한다.The present invention relates to an ultrahigh pressure onion extract (hereinafter, referred to as " high-pressure onion extract ") which is subjected to ultra-high pressure treatment at 400 to 800 MPa for 0.5 minute to 5 hours and contains quercetin 4'-glycoside and quercetin 3,4'- As an active ingredient, a health functional food composition for lowering cholesterol in blood.
상기 건강기능식품 조성물에서, 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.In the health functional food composition, the kind of the food is not particularly limited. Examples of the foods to which the above substances can be added include dairy products including dairy products, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, Beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, all of which include health functional foods in a conventional sense.
본 발명의 상기 초고압 양파 추출물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강식품 중의 상기 화합물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The hyperbaric onion extract of the present invention can be added directly to food or used together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). Generally, the amount of the compound in the health food may be 0.1 to 90 parts by weight of the total food. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
음료를 제조하는 경우 지시된 비율로 필수 성분으로서 상기 초고압 양파 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.When the beverage is manufactured, there are no particular restrictions on the other components other than those containing the ultra-high pressure onion extract as an essential ingredient at the indicated ratios, and may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 of the composition of the present invention.
상기 외에 본 발명의 초고압 양파 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 초고압 양파 추출물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. In addition to the above, the ultrahigh pressure onion extract of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and heavies (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the ultra high pressure onion extract of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 초고압 양파 추출물 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
These components may be used independently or in combination. The proportion of such additives is not so important, but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the ultra high pressure onion extract of the present invention.
본 발명은 상기 제조방법으로 제조된 혈중 콜레스테롤 농도 저하 활성을 갖는 초고압 양파 추출물을 유효성분으로 하는 혈중 콜레스테롤 고함량에 의해 유발되는 비만, 고지혈증, 혈전증, 동맥경화, 뇌졸증 또는 심근경색의 치료 및 예방용 약학 조성물을 제공한다.The present invention relates to a method for the treatment and prevention of obesity, hyperlipidemia, thrombosis, arteriosclerosis, stroke or myocardial infarction caused by high blood cholesterol content, which comprises an ultra high pressure onion extract having blood cholesterol concentration lowering activity, To provide a pharmaceutical composition.
본 발명은 400 내지 800 MPa에서 0.5 분 내지 5 시간 초고압 처리되고, 지표성분으로 퀘르세틴 4'-글리코시드와 퀘르세틴 3,4'-글리코시드를 1:8 내지 1:10로 포함하는, 초고압 양파 추출물을 유효성분으로 하는 혈중 콜레스테롤 고함량에 의해 유발되는 비만, 고지혈증, 혈전증, 동맥경화, 뇌졸증 또는 심근경색의 치료 및 예방용 약학 조성물을 제공한다.The present invention relates to an ultrahigh pressure onion extract (hereinafter, referred to as " high-pressure onion extract ") which is subjected to ultra-high pressure treatment at 400 to 800 MPa for 0.5 minute to 5 hours and contains quercetin 4'-glycoside and quercetin 3,4'- A hyperlipemia, a thrombosis, atherosclerosis, a stroke or myocardial infarction caused by a high content of blood cholesterol comprising as an active ingredient.
본 발명의 약학 조성물은 약제의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of medicaments.
본 발명에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화 하여 사용될 수 있다. 본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method . Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘(calcium carbonate), 슈크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤젤라틴 등이 사용될 수 있다.In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may be formulated into the compositions of the present invention with at least one excipient such as starch, calcium carbonate, (sucrose), lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a suppository base, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol gelatin and the like can be used.
본 발명의 약학 조성물은 경구 또는 비경구로 투여될 수 있으며, 비경구 투여법이라면 어느 것이나 사용 가능하고, 전신 투여 또는 국소 투여가 가능하나, 전신 투여가 더 바람직하며, 정맥 내 투여가 가장 바람직하다.The pharmaceutical composition of the present invention can be administered orally or parenterally. Any parenteral administration method can be used, and systemic administration or local administration is possible, but systemic administration is more preferable, and intravenous administration is most preferable.
본 발명의 약학 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.0001 내지 0.03 g/kg으로, 바람직하게는 0.001 내지 8 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.
The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at 0.0001 to 0.03 g / kg per day, preferably 0.001 to 8 mg / kg per day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 400 내지 800 MPa로 초고압에서도 매우 높은 압력으로 처리한 초고압 양파 추출물은 종래 통상의 방법으로 제조한 양파 추출물과 퀘르세틴 함량은 유사하거나 오히려 상대적으로 낮음에도 불구하고, 혈중 콜레스테롤 농도를 저하시키는 HMG-CoA 환원효소 억제 활성이 현저히 증대되고, 양파 특유의 불쾌취를 부여하는 황 화합물의 함량이 낮아지므로, 양파 냄새로 인한 거부감 없이 혈중 콜레스테롤 고함량에 의해 유발되는 비만, 고지혈증, 혈전증, 동맥경화, 뇌졸증 또는 심근경색의 치료 및 예방용 약학 조성물이나 혈중 콜레스테롤 강하용 건강기능식품 조성물의 유효성분으로 활용될 수 있다.
The high pressure onion extract treated with an extremely high pressure even at an ultra-high pressure of 400 to 800 MPa according to the present invention has a similar or even relatively low quercetin content to onion extract prepared by conventional methods, -COA < / RTI > reductase inhibitory activity is remarkably increased and the content of sulfur compound giving unpleasant odor unique to onion is lowered. Therefore, it is possible to prevent obesity, hyperlipemia, thrombosis, arteriosclerosis, A pharmaceutical composition for the treatment and prevention of stroke or myocardial infarction, and a health functional food composition for lowering blood cholesterol.
이하, 바람직한 실시예를 들어 본 발명을 더욱 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이에 의하여 제한되지 않는다는 것은 당업계의 통상의 지식을 가진 자에게 자명 할 것이다.
Hereinafter, the present invention will be described in more detail with reference to preferred embodiments. It will be apparent, however, to those skilled in the art that these embodiments are for further explanation of the present invention and that the scope of the present invention is not limited thereby.
비교예 1: 양파 열수 추출물 분말 제조Comparative Example 1: Production of onion hot-water extract powder
양파는 무안산으로 전남서남부채소농협에서 구입하였으며 크기 약 300g 내외의 것을 가식부만 2× 2 cm로 세절하여 100 g 씩 균일하게 나눠 사용하였다.Onions were purchased from Mongsan, Jeollanam-do, South Jeolla Province, Korea. The onion was cut into 2 × 2 cm by 100 g.
상기 양파 100 g 에 물 200 mL를 첨가한 후, 100 ℃에서 1시간 동안 추출하고, 이를 여과하여 추출액을 얻어 냉동진공건조기를 사용하여 양파 열수 추출물 분말을 제조하였다.
200 mL of water was added to 100 g of the onion, and the mixture was extracted at 100 ° C. for 1 hour. The extract was filtered to obtain an onion hot-water extract powder using a freeze-dried vacuum dryer.
제조예 1: 초고압 처리 압력에 따른 초고압 양파 추출물 분말의 제조Production Example 1: Preparation of ultra-high pressure onion extract powder according to ultrahigh pressure treatment pressure
상기 비교예 1에서 사용한 것과 같은 양파 100 g 을 온도 20 ℃에서, 각각 0, 100, 250, 500 및 600 Mpa 초고압으로 5 분간 처리 후, 상기 초고압 처리 양파에 물 200 mL를 첨가한 후, 믹서기로 분쇄하고, 이를 여과하고 추출액을 얻어 냉동진공건조기를 사용하여 양파 추출물 분말을 제조하였다.
100 g of the same onion as used in Comparative Example 1 was treated at a high temperature of 0, 100, 250, 500 and 600 Mpa for 5 minutes at a temperature of 20 캜, 200 mL of water was added to the ultra high pressure treated onion, The extract was filtered, and an extract was obtained and onion extract powder was prepared using a freeze-dried vacuum dryer.
제조예 2: 초고압 처리 시간에 따른 초고압 양파 추출분말의 제조Production Example 2: Preparation of ultra-high pressure onion extract powder according to ultrahigh pressure treatment time
상기 비교예 1에서 사용한 것과 같은 양파 100 g 을 온도 20 ℃에서, 500 Mpa 초고압으로 각각 5 분, 10 분, 30 분 및 60 분 처리 후, 상기 초고압 처리 양파에 물 200 mL를 첨가한 후, 믹서기로 분쇄하고, 이를 여과하고 추출액을 얻어 냉동진공건조기를 사용하여 양파 추출물 분말을 제조하였다.
100 g of the same onion as used in Comparative Example 1 was treated for 5, 10, 30, and 60 minutes at a temperature of 20 캜 and 500 MPa and at an ultra-high pressure, respectively. After 200 mL of water was added to the ultra- , And the resulting mixture was filtered to obtain an extract, and onion extract powder was prepared using a freeze-dried vacuum dryer.
제조예 3: 물추출 온도 및 시간에 따른 초고압 양파 추출분말의 제조Preparation Example 3: Preparation of ultra-high pressure onion extract powder according to water extraction temperature and time
상기 비교예 1에서 사용한 것과 같은 양파 100 g 을 온도 20 ℃에서, 500 Mpa 초고압으로 5 분 처리 후, 상기 초고압 처리 양파에 20 ℃의 물 200 mL를 첨가한 후, 믹서기로 분쇄하고, 각각 0, 1, 3, 5 및 7 시간 추출한 후 이를 여과하고 추출액을 얻어 냉동진공건조기를 사용하여 양파 추출물 분말을 제조하였다.100 g of the same onion as used in Comparative Example 1 was treated at a temperature of 20 캜 for 5 minutes at a high pressure of 500 MPa and 200 mL of water at 20 캜 was added to the above ultra high pressure treated onion and then pulverized with a blender, After 1, 3, 5 and 7 hours of extraction, the extracts were filtered, and onion extract powder was prepared using a freeze-dried vacuum dryer.
또한 상기와 동일하게 초고압 처리한 후, 상기 초고압 처리 양파에 90 ℃의 물 200 mL를 첨가한 후, 믹서기로 분쇄하고, 각각 1, 3, 5 및 7 시간 추출한 후 이를 여과하고 추출액을 얻어 냉동진공건조기를 사용하여 양파 추출물 분말을 제조하였다.
Also, 200 mL of water at 90 ° C was added to the ultra-high pressure treated onion, and the mixture was pulverized with a blender and extracted for 1, 3, 5 and 7 hours, Onion extract powder was prepared using a dryer.
제조예 4: 에탄올 추출 시간에 따른 초고압 양파 추출분말의 제조Production Example 4: Preparation of ultra-high pressure onion extract powder according to ethanol extraction time
상기 비교예 1에서 사용한 것과 같은 양파 100 g 을 온도 20 ℃에서, 500 Mpa 초고압으로 5 분 처리 후, 상기 초고압 처리 양파에 20 ℃의 에탄올 200 mL를 첨가한 후, 믹서기로 분쇄하고, 각각 1, 3, 5 및 7 시간 추출한 후 이를 여과하고 추출액을 얻어 냉동진공건조기를 사용하여 양파 추출물 분말을 제조하였다.
100 g of the same onion as used in Comparative Example 1 was treated at a temperature of 20 캜 for 5 minutes at a high pressure of 500 MPa, and 200 mL of ethanol at 20 캜 was added to the ultra high pressure treated onion, followed by pulverization with a mixer. After 3, 5 and 7 hours of extraction, the extracts were filtered and the onion extract powder was prepared using a freeze-dried vacuum dryer.
실험예 1: HMG-CoA 환원효소 저해 활성Experimental Example 1: HMG-CoA reductase inhibitory activity
상기 비교예 1 및 제조예 1 내지 4에서 얻은 양파 추출물 분말 시료의 콜레스테롤 저해능을 측정하였다. The cholesterol-lowering ability of the onion extract powder samples obtained in Comparative Example 1 and Preparation Examples 1 to 4 was measured.
HMG-CoA는 HMG CoA reductase를 통해 Mevalonate가 되며 이는 콜레스테롤을 생성 한다. 이런 과정에서 생체 내 HMG CoA 환원효소(reductase)의 활성이 높아질수록 콜레스테롤 합성이 높아진다. 그러므로 샘플의 HMG CoA 환원효소 저해 활성을 통해 콜레스테롤 저해 활성을 측정하였다. 대조군으로 물을 사용하였고, 96 well에 상기 시료 또는 대조군 1 ㎕ 첨가하고, 1x assay buffer 181 ㎕와 NADPH 4 ㎕, HMGR 효소 2 ㎕, HMG-CoA 12 ㎕를 첨가하였다. 37℃에서 10분간 kinetic으로 흡광도 변화를 확인하였다. 시료의 HMG CoA 환원효소 활성은 대조군을 100%로 하였을 때의 효소 활성의 저해율을 나타내었다. 시료의 농도는 양파 생물 5 g에 해당되는 양만큼 계산하여 투입하였다.HMG-CoA is converted to mevalonate via HMG CoA reductase, which produces cholesterol. In this process, the higher the activity of HMG CoA reductase in vivo, the higher the cholesterol synthesis. Therefore, the cholesterol inhibitory activity was measured by the HMG CoA reductase inhibitory activity of the sample. Water was used as a control, and 1 μl of the above sample or control was added to 96 wells. 181 μl of 1 × assay buffer, 4 μl of NADPH, 2 μl of HMGR enzyme, and 12 μl of HMG-CoA were added. The change in absorbance was monitored by kinetic at 37 ° C for 10 min. The HMG CoA reductase activity of the samples showed the inhibition rate of the enzyme activity when the control group was taken as 100%. The concentration of the sample was calculated by adding the amount equivalent to 5 g of onion creature.
먼저 표 1에는 제조예 1의 초고압 처리 압력을 달리하였을 때의 HMG CoA 환원효소의 저해 활성을 나타내었다.Table 1 shows the inhibitory activity of HMG CoA reductase when the ultrahigh pressure treatment pressure of Preparation Example 1 was varied.
초고압 처리 압력 100 MPa까지는 HMG CoA 환원효소의 저해 활성이 거의 나타나지 않았었고, 250 MPa의 경우에도 열수 추출한 비교예 1에 비해 낮은 저해 활성을 나타내었으나, 500 MPa 이상에서는 250 MPa로 처리한 시료나 비교예 1에 비해 현저히 높은 HMG CoA 환원효소의 저해 활성을 나타내었다.The inhibition activity of HMG CoA reductase was hardly observed at the pressure of 100 MPa at the ultrahigh pressure, and the inhibitory activity of 250 MPa was lower than that of Comparative Example 1 at 250 MPa. The inhibitory activity of HMG CoA reductase was significantly higher than that of Example 1.
다음으로 표 2에는 제조예 2의 초고압 처리 시간을 달리하였을 때의 HMG CoA 환원효소의 저해 활성을 나타내었다.Next, Table 2 shows the inhibitory activity of HMG CoA reductase when the ultrahigh pressure treatment time of Preparation Example 2 was varied.
초고압 처리 시간 5 분에서 30 분까지는 HMG CoA 환원효소의 저해 활성에서 거의 차이가 없었고, 60 분에서는 오히려 저해 활성이 오히려 감소됨을 확인하였다. The inhibition activity of HMG CoA reductase from 5 minutes to 30 minutes of ultrahigh pressure treatment was not significantly different, and the inhibitory activity was rather reduced at 60 minutes.
다음으로 표 3에는 제조예 3의 물추출 온도 및 시간에 따른 HMG CoA 환원효소의 저해 활성을 나타내었다.Table 3 shows the inhibitory activity of HMG CoA reductase according to the water extraction temperature and time of preparation example 3.
물 추출 온도는 HMG CoA 환원효소의 저해 활성에서 거의 영향을 주지 않았으나, 물 추출 직후 저행 활성이 가장 높고, 추출 시간이 길어질수록 오히려 저해 활성이 낮아지는 것을 확인할 수 있었다. 이는 특히 물 추출 시간일 길어질수록 퀘르세틴 추출량은 증대된다는 점에서, 물 추출 시간이 길어질수록 퀘르세틴이 아닌 별개의 HMG CoA 환원효소의 저해 활성을 나타내는 유효성분이 분해될 수 있다고 추정할 수 있었다.The water extraction temperature had little effect on the inhibitory activity of HMG CoA reductase, but it was found that the low activity was the highest immediately after the water extraction and the inhibitory activity decreased as the extraction time was longer. This suggests that as the water extraction time becomes longer, the active ingredient which is different from quercetin may be degraded, which exhibits the inhibitory activity of HMG CoA reductase, especially since the quercetin extraction amount increases as the water extraction time becomes longer.
다음으로 표 4에는 제조예 4의 초고압 처리 시간을 달리하였을 때의 HMG CoA 환원효소의 저해 활성을 나타내었다.Next, Table 4 shows the inhibitory activity of HMG CoA reductase when the ultrahigh pressure treatment time of Preparation Example 4 was varied.
물 추출과 마찬가지로 에탄올 추출에서도 추출 시간이 길어질수록 오히려 저해 활성이 낮아지는 것을 확인할 수 있었다.
Similar to water extraction, ethanol extraction also showed that the longer the extraction time, the lower the inhibitory activity.
상기 결과로부터 초고압 처리 압력은 500 내지 600 MPa을 유지하고, 초고압 처리 시간은 5 내지 10 분이면 충분하고, 추출시간을 1 시간 이내로 짧게 하거나 착즙하는 것이 HMG CoA 환원효소의 저해 활성이 뛰어난 초고압 양파 추출물을 얻는데 바람직함을 확인하였다.
From the above results, the ultrahigh pressure treatment pressure was maintained at 500 to 600 MPa, the ultrahigh pressure treatment time was sufficient for 5 to 10 minutes, and the extraction time was shortened to 1 hour or less to obtain an ultra high pressure onion extract having excellent inhibitory activity of HMG CoA reductase . ≪ / RTI >
실험예 2: 퀘르세틴 함량 분석Experimental Example 2: Quercetin content analysis
본 발명의 초고압 양파 추출물의 초고압 처리 조건과 퀘르세틴 함량의 상관관계를 분석하기 위해서, 처리 조건에 따라 HMG CoA 환원효소의 저해 활성의 변화가 큰 제조예 1의 시료를 이용하여 퀘르세틴 2,4'-디글루코시드, 퀘르세틴 3-글루코시드, 퀘르세틴 4'-글루코시드 및 퀘르세틴 비배당체와 총 퀘르세틴 함량을 분석하여 표 5에 나타내었다. 퀘르세틴 함량은 양파 생물 100 g으로 환산했을 때의 퀘르세틴의 mg 함량, 즉 mg/100 g equivalent로 나타내었다.In order to analyze the correlation between the ultra-high pressure treatment conditions and the quercetin content of the ultrahigh pressure onion extract of the present invention, the sample of Preparation Example 1, in which the inhibitory activity of HMG CoA reductase was greatly changed according to the treatment conditions, Glucuronide, quercetin 4'-glucoside, quercetin non-glycoside and total quercetin content were analyzed and shown in Table 5. The quercetin content was expressed as mg of quercetin when converted to 100 g of onion creature, that is, mg / 100 g equivalent.
퀘르세틴 분석은 70% 메탄올(2% 초산 함유)을 이용하여 시료의 쿼세틴을 추출하였으며 Agilent 1100 series를 이용하여 분석하였고, 최대 흡수파장인 370 nm에서 TSK gel ODS-120T Column 4.6 × 250 mm를 사용하여 정량 분석하였다. 표준물질로 퀘르세틴류의 Quercetin-3,4'-O-diglucoside, Quercetin-3-O-glucoside, Quercetin-4'-monoglucoside, Quercetin을 사용하였다. 시험용액의 제조 및 분석은 시료 0.2 g을 70% 메탄올(2% 초산 함유) 4 mL와 혼합해 10 분간 초음파 처리 및 0.45 ㎛의 멤브레인 필터로 여과한 것을 시험용액으로 사용하였다. 이동상은 solvent A (물:메탄올:초산 = 69:29:2)와 solvent B (물:메탄올:초산 =29:69:2)로 사용하였다.Quercetin was extracted from the sample using 70% methanol (containing 2% acetic acid) and analyzed using Agilent 1100 series. Using the TSK gel ODS-120T column 4.6 × 250 mm at 370 nm And analyzed quantitatively. Quercetin-3,4'-O-diglucoside, Quercetin-3-O-glucoside, Quercetin-4'-monoglucoside and Quercetin were used as standard substances. For the preparation and analysis of the test solution, 0.2 g of the sample was mixed with 4 mL of 70% methanol (containing 2% acetic acid), and the mixture was ultrasonicated for 10 minutes and filtered through a 0.45 μm membrane filter. The mobile phase was used as solvent A (water: methanol: acetic acid = 69: 29: 2) and solvent B (water: methanol: acetic acid = 29: 69: 2).
상기 표 5의 결과를 표 1의 HMG CoA 환원효소의 저해 활성 결과와 함께 대비해서 살펴보면, 초고압 처리 압력이 100 MPa에서 600 MPa로 높아질 때, 총 퀘르세틴 함량은 감소하였고, HMG CoA 환원효소의 저해 활성은 오히려 증가하였음을 알 수 있었다. 특히 500 MPa 이상에서는 양파 열수 추출물인 비교예 1에 비해서 총 퀘르세틴 함량이 15 내지 20 % 낮은 값이었지만, HMG CoA 환원효소의 저해 활성은 현저히 높다는 것을 알 수 있었다.
The results of Table 5 were compared with the results of inhibition activity of HMG CoA reductase shown in Table 1. When the ultrahigh pressure treatment pressure was increased from 100 MPa to 600 MPa, the total quercetin content decreased and the inhibitory activity of HMG CoA reductase Was increased. In particular, it was found that the total quercetin content was 15 to 20% lower than that of Comparative Example 1, which is an onion hydrothermal extract, above 500 MPa, but the inhibitory activity of HMG CoA reductase was remarkably high.
실험예 3: 퀘르세틴 혼합물과 초고압 양파 추출물의 HMG-CoA 환원효소 저해 활성 비교Experimental Example 3: Comparison of HMG-CoA reductase inhibitory activity of quercetin mixture and ultrahigh pressure onion extract
제조예 1의 양파 100 g 을 온도 20 ℃에서, 500 Mpa 초고압으로 5 분간 처리 후, 상기 초고압 처리 양파에 물 200 mL를 첨가한 후, 믹서기로 분쇄하고, 이를 여과하고 추출액을 얻어 냉동진공건조기를 사용하여 양파 추출물 분말을 제조하였다. 이때의 양파 추출물 분말의 수율은 6.19 %이었고, 이때의 퀘르세틴 함량은 표 6에 나타내었다. 또한 실험예 2에서 사용한 Quercetin-3,4'-O-diglucoside, Quercetin-3-O-glucoside, Quercetin-4'-monoglucoside, Quercetin 표준물질을 표 6의 500 MPa 양파 추출물과 동일한 조성으로 혼합하여 퀘르세틴 혼합물을 제조하였다.100 g of the onion of Preparation Example 1 was treated at a temperature of 20 캜 for 5 minutes at a high pressure of 500 MPa, and then 200 mL of water was added to the ultra-high pressure treated onion, followed by pulverization with a blender, filtration, Onion extract powder was prepared. The yield of the onion extract powder at this time was 6.19%, and the quercetin content at this time is shown in Table 6. Quercetin-3,4'-O-diglucoside, Quercetin-3-O-glucoside, Quercetin-4'-monoglucoside and Quercetin standard substances used in Experimental Example 2 were mixed in the same composition as the 500 MPa onion extract shown in Table 6, A mixture was prepared.
상기 제조예 1의 500 MPa 양파 추출물 분말과 표준물질을 혼합한 퀘르세틴 혼합물을 양파 생물 0.5 g에 해당하는 양(500 MPa 양파 추출물 분말 0.31 g)만큼 투입하였고, 양성 대조군으로 스타틴(statin) 44.6 ㎍/mL 농도로 사용하여 실험예 1과 동일한 방법으로 HMG CoA 환원효소의 저해 활성을 측정하여 표 7에 나타내었다.The quercetin mixture containing the 500 MPa onion extract powder of Preparation Example 1 and the standard substance was added in an amount corresponding to 0.5 g of onion creature (0.31 g of 500 MPa onion extract powder), and statin 44.6 ㎍ / mL, the inhibitory activity of HMG CoA reductase was measured in the same manner as in Experimental Example 1, and the results are shown in Table 7.
상기 표 7에 따르면, 퀘르세틴 혼합물은 500 MPa 양파 추출물과 동일한 함량과 조성으로 퀘르세틴을 포함하고 있음에도, 500 MPa 양파 추출물에 비해 HMG CoA 환원효소의 저해 활성은 현저히 낮다는 것을 알 수 있었다. 이를 고려했을 때 본 발명의 초고압 양파 추출물에는 HMG CoA 환원효소의 저해 활성을 가지는 유효성분으로 퀘르세틴 이외의 물질을 함유하고 있음을 추정할 수 있었다.
According to the above Table 7, although the quercetin mixture contains quercetin in the same content and composition as the 500 MPa onion extract, the inhibitory activity of the HMG CoA reductase is remarkably lower than that of the 500 MPa onion extract. Considering this fact, it can be inferred that the ultra high pressure onion extract of the present invention contains substances other than quercetin as an active ingredient having HMG CoA reductase inhibitory activity.
실험예 4: 초고압 처리 압력에 따른 초고압 양파 추출물의 황 화합물 분석Experimental Example 4: Sulfur compound analysis of ultra high pressure onion extract according to ultrahigh pressure treatment pressure
본 발명의 초고압 양파 추출물의 초고압 처리 조건과 황 화합물의 상관관계를 분석하기 위해서, 제조예 1의 초고압 처리 압력을 달리하였을 때의 디메틸 디설파이드(DMDS), 디메틸 트리설파이드(DMTS), 알릴 설파이드, 알릴 디설파이드 및 알릴 트리설파이드(ATS) 함량 및 총 황 화합물 함량(mg/100 g equivalent)을 분석하여 표 8에 나타내었다. 황 화합물 함량은 양파 생물 100 g으로 환산했을 때의 황 화합물 mg의 함량, 즉 mg/100 g 양파 생물 당량으로 나타내었다. (DMDS), dimethyltrisulfide (DMTS), allyl sulfide, allyl sulfide (DMTS), and the like were used in order to analyze the correlation between the ultrahigh pressure treatment conditions and the sulfur compounds of the ultra high pressure onion extract of the present invention, The disulfide and allyl trisulfide (ATS) contents and the total sulfur compound contents (mg / 100 g equivalent) were analyzed and are shown in Table 8. The content of sulfur compound is expressed as mg of sulfur compound in terms of onion creature converted to 100 g, that is, mg / 100 g onion bioequivalent.
함황화합물 분석은 50% 아세토니트릴을 이용하여 시료의 함황화합물을 추출하였으며 Agilent 1100 series를 이용하여 분석하였고, 최대 흡수파장인 208 nm에서 Hypurity Elite C18 Column 3 × 150 mm를 사용하여 정량 분석하였다. 표준물질로 디메틸 디설파이드, 디메틸 트리설파이드, 알릴 설파이드, 알릴 디설파이드, 알릴 트리설파이드를 사용하였다. 시험용액의 제조 및 분석은 시료 0.5 g을 50 % 아세토니트릴 1 mL와 혼합해 10 분간 초음파 처리 및 0.45 ㎛의 멤브레인 필터로 여과한 것을 시험용액으로 사용하였다. 이동상은 solvent A (20 mM NaH₂PO₄H₂O(pH2.1) + 10 mM Heptan sulfonic acid sodium salt)와 solvent B (물:메탄올:초산 =29:69:2)로 사용하였다. The sulfur compounds of the samples were extracted with 50% acetonitrile, analyzed using Agilent 1100 series, and analyzed quantitatively using a Hypurity Elite C18 Column 3 × 150 mm at a maximum absorption wavelength of 208 nm. Dimethyl disulfide, dimethyl trisulfide, allyl sulfide, allyl disulfide, and allyl trisulfide were used as standard materials. For the preparation and analysis of the test solution, 0.5 g of the sample was mixed with 1 mL of 50% acetonitrile, sonicated for 10 minutes, and filtered through a 0.45 μm membrane filter. The mobile phase was used as solvent A (20 mM NaH 2 PO 4 H 2 O (pH 2.1) + 10 mM Heptane sulfonic acid sodium salt) and solvent B (water: methanol: acetic acid = 29: 69: 2).
초고압 처리 압력 250 MPa까지는 비교예 1에 비해 오히려 황 화합물의 함량이 매우 높게 나타났으나, 500 MPa 이상부터는 황 화합물 중에서 DMDS 및 DMTS 함량이 감소하면서 총 황 화합물의 함량이 비교예 1의 1/4 내지 1/5 수준으로 현저히 감소하였음을 확인할 수 있었다.However, when the pressure was 250 MPa, the content of sulfur compounds was higher than that of Comparative Example 1. However, when the content of sulfur compounds was higher than 500 MPa, the contents of DMDS and DMTS were decreased, To 1/5 level.
Claims (10)
상기 초고압 양파 추출물의 지표성분으로 퀘르세틴 4'-글리코시드와 퀘르세틴 3,4'-글리코시드의 중량비가 1:8 내지 1:10 인 것을 특징으로 하는 혈중 콜레스테롤 농도 저하 활성을 갖는 초고압 양파 추출물의 제조방법.Treating the onion at 400 to 800 MPa for 0.5 to 5 hours at an ultra-high pressure; And extracting or extracting the ultra-high pressure processed onion, the method comprising the steps of:
Characterized in that the weight ratio of quercetin-4'-glycoside to quercetin-3,4'-glycoside is 1: 8 to 1:10 as an index component of the ultra high-pressure onion extract. Way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130048451A KR101466633B1 (en) | 2013-04-30 | 2013-04-30 | Preparation method for ultra-high pressure extract of onion having reducing activity of serum cholesterol and pharmaceutical or neutraceutical composition comprising the extract of onion as an effective ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130048451A KR101466633B1 (en) | 2013-04-30 | 2013-04-30 | Preparation method for ultra-high pressure extract of onion having reducing activity of serum cholesterol and pharmaceutical or neutraceutical composition comprising the extract of onion as an effective ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140129752A KR20140129752A (en) | 2014-11-07 |
| KR101466633B1 true KR101466633B1 (en) | 2014-11-28 |
Family
ID=52292133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130048451A KR101466633B1 (en) | 2013-04-30 | 2013-04-30 | Preparation method for ultra-high pressure extract of onion having reducing activity of serum cholesterol and pharmaceutical or neutraceutical composition comprising the extract of onion as an effective ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101466633B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170024804A (en) | 2015-08-26 | 2017-03-08 | 철원친환경영농조합법인 | Food composition comprising organically grown siberian ginseng, onion and ginger enzyme and method of manufacturing the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073490B1 (en) * | 2018-10-31 | 2020-02-04 | 심상희 | Tablet-typed portable handy food substitue and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004229615A (en) | 2003-01-31 | 2004-08-19 | New Industry Research Organization | Quercetin composition, food preservative, and method for producing the same |
| JP2008533113A (en) | 2005-03-14 | 2008-08-21 | スカリム ニュトリシオン | Use of onion extract in the manufacture of weight gain control compositions |
| KR20090112432A (en) * | 2008-04-24 | 2009-10-28 | 우송대학교 산학협력단 | Developement of natural sweetener for diabetes and hypertension blood pressure patients |
| KR20110100882A (en) * | 2010-03-05 | 2011-09-15 | 인제대학교 산학협력단 | Composition comprising quercetin for preventing or treating lipid metabolism disorder |
-
2013
- 2013-04-30 KR KR1020130048451A patent/KR101466633B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004229615A (en) | 2003-01-31 | 2004-08-19 | New Industry Research Organization | Quercetin composition, food preservative, and method for producing the same |
| JP2008533113A (en) | 2005-03-14 | 2008-08-21 | スカリム ニュトリシオン | Use of onion extract in the manufacture of weight gain control compositions |
| KR20090112432A (en) * | 2008-04-24 | 2009-10-28 | 우송대학교 산학협력단 | Developement of natural sweetener for diabetes and hypertension blood pressure patients |
| KR20110100882A (en) * | 2010-03-05 | 2011-09-15 | 인제대학교 산학협력단 | Composition comprising quercetin for preventing or treating lipid metabolism disorder |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170024804A (en) | 2015-08-26 | 2017-03-08 | 철원친환경영농조합법인 | Food composition comprising organically grown siberian ginseng, onion and ginger enzyme and method of manufacturing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140129752A (en) | 2014-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2854828B1 (en) | A method of preparing a panax spp. plant extract with increased content ratio of ginsenoside rg3, rg5, and rk1 produced by microwave irradiation | |
| EP3116520B1 (en) | Phytocomplexes from citrus bergamia | |
| KR101392204B1 (en) | Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases | |
| TW201542213A (en) | Anti-obesity composition | |
| KR20200125155A (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of radish leave | |
| JP2003342185A (en) | Inhibitor of lipase activity | |
| KR20160125019A (en) | Composition for preventing, improving or treating cornea damages containing extracts of diospyros kaki | |
| KR101466633B1 (en) | Preparation method for ultra-high pressure extract of onion having reducing activity of serum cholesterol and pharmaceutical or neutraceutical composition comprising the extract of onion as an effective ingredient | |
| KR20170073293A (en) | Composition for treatment, improvement or prevention of pulmonary diseases comprising extract of platycarya strobilacea leaf, birch bark or inonotus obliquus as an effective component | |
| KR102331317B1 (en) | Composition for improving premenstrual syndrome symptom comprising compounds isolated from Chrysanthemum zawadskii extract | |
| KR101645991B1 (en) | Pharmaceutical composition for prevention or treatment of blood vessel disease containing extracts of Morus alba stem having activity preventing from the atherogenic legion formation and foam cell formation | |
| JP2010184886A (en) | New compound | |
| KR101286035B1 (en) | Method to increase the concentration of components on ginseng prosapogenins using microwave against the aerial part of ginseng | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
| KR101381850B1 (en) | Composition comprising curcuma longa extract having anti-cholesterol activities and the method curcuma longa extract | |
| KR102429147B1 (en) | A method for manufacturing kolaviron | |
| JP2010512382A (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABE CONTAINING SICONIN COMPOUND AND USE | |
| KR102535521B1 (en) | Fruits of Acanthopanax Sessiliflorus extract including diabetes prevention functional ingredients and method for manufacturing it | |
| KR20170076587A (en) | Composition comprising Monoterpenyl magnolol as an effective ingredient for preventing or treating of obesity, hyperlipidemia or fatty Liver and Method for preparing fraction of Magnolia cortex | |
| KR102087165B1 (en) | Pharmaceutical composition for Anti-oxidative or Anti-inflammatory comprising extract processed by Enzymatic hydrolysis of the Bark of Eleutherococcus sessiliflorus | |
| KR101222845B1 (en) | Composition comprising reacted mixture of red ginseng extract and persimmon vinegar for treating or preventing vascular diseases | |
| KR20130000017A (en) | Composition for preventing and treating diabetics containing active ingredients separated from sorghum | |
| KR20170001681A (en) | Preparation method for Magnolia cortex extract with an enhanced content of honokiol and magnolol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20171227 Year of fee payment: 6 |